Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018

MKGAF

Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

PR Newswire

DARMSTADT, Germany, March 20, 2018 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany (XETRA: MRK, OTC Pink: MKKGY), a leading science and technology company, today announced that it will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on 22nd March 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.

DATE:

March 22nd, 2018

TIME:   

11.30am ET

LINK:  

https :// tinyurl . com / dbvic 03 prepr

This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Participation is free of charge.

It is recommended that investors pre-register to save time and receive event updates.

Recent Company Highlights

  • Merck Achieves Targets for 2017 – Dividend to Increase
  • Merck Announced Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
  • Mavenclad (Cladribine Tablets) Receives First Approval in Latin America, following approval in the EU, Canada, Australia and Israel
  • Merck Receives Patents for CRISPR Technology in U.S., Brazil, China, India, Japan, South Korea and Israel

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.

 

Cision View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-to-present-at-the-dbvic---deutsche-bank-adr-virtual-investor-conference-on-22nd-march-2018-300616458.html

SOURCE Merck KGaA



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today